Meanwhile, the European Medicines Agency in London announced it would review drugs similar to Vioxx.
I couldn't see Merck saying we're going to market a drug with a safety problem.
"When there are other alternatives, why risk trying to use the drug that might have elevated risk?
Kim, Frazier and Gilmartin gathered in the chief executive's conference room at the Whitehouse Station, N.J., campus.
The FDA safety officer in charge of the report, David Graham, concluded that Vioxx posed much greater cardiovascular risk than the other major drug in its class, Celebrex.